ArticleBlood cancer journal2025

Treatment outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg-type in the rituximab era.

Giulio Cassanello et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.